If you're searching for information about Samsung investing in Exo or looking to learn more about AI-powered medical imaging devices, you're in the right place. Samsung’s venture capital arm is reportedly considering a major investment—up to $100 million—in Exo, a cutting-edge medical imaging startup based in California. This move signals Samsung’s continued expansion into the digital health and ultrasound device markets, where demand for portable and AI-enhanced diagnostic tools is growing rapidly.
According to a Bloomberg report, the funding round is being led by Sands Capital, Bold Capital, and Qubit Health Capital. Notably, Qubit’s chairman, Omar Ishrak—former CEO of Medtronic and a leading figure in the medical device industry—is expected to join Exo’s board, further validating the startup’s growth trajectory and technological promise.
Founded in 2015, Exo develops advanced handheld ultrasound devices that integrate artificial intelligence, silicon-based hardware, and mobile-first software solutions. These tools allow healthcare professionals to perform quick and accurate scans, such as lung assessments or echocardiograms, directly from a smartphone. Through its all-in-one platform, users can scan patients, document findings, and securely share reports—enhancing both workflow and patient care.
To date, Exo has raised over $320 million in funding from major institutional investors including RA Capital Management, BlackRock, Intel, Sony, and Avidity Partners. Its most recent fundraising event was a $220 million Series C round in 2021. With this potential new backing from Samsung, Exo is poised to further disrupt the $8+ billion global ultrasound market.
Additionally, discussions are reportedly underway between Exo and Samsung Medison, a Samsung subsidiary focused on diagnostic ultrasound and digital X-ray systems. A strategic partnership could enhance Samsung’s footprint in portable medical imaging, while accelerating Exo’s global reach and commercialization strategy.
The convergence of AI, portable diagnostics, and mobile health technology has made this sector a hotbed for high-return investment, with significant implications for healthcare providers, hospital systems, and emergency medicine. Should this deal proceed, it would represent not just a financial milestone for Exo, but also a critical step forward in making advanced diagnostics more accessible, affordable, and scalable worldwide.
As of now, Exo, Samsung, and the participating venture capital firms have not commented publicly on the reported investment. However, all signs point to a game-changing partnership that could redefine the landscape of medical imaging technology.
Post a Comment